CTLA4 and neoplasm: Moreover, PCa patients with higher ATRS had lower CYT scores, while no significant difference in neoantigens and tumor mutation burdens was observed between high and low ATRS patients (Figure S10B–E), and the correlation of neoantigens and tumor mutations of PRAD was displayed in Figure S10F. For IPS, the correlation of IPS, IPS PD1 blocker, IPS CTLA4, and IPS PD1 and CTLA4 with ATRS was not observed in PCa patients (Figure S10G–J).